Protagonist Other Liab vs Common Stock Analysis

PTGX Stock

USD 42.67 0.50 1.16%

Protagonist Therapeutics financial indicator trend analysis is much more than just breaking down Protagonist Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagonist Therapeutics is a good investment. Please check the relationship between Protagonist Therapeutics Other Liab and its Common Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Other Liab vs Common Stock

Other Liab vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagonist Therapeutics Other Liab account and Common Stock. At this time, the significance of the direction appears to have no relationship.

The correlation between Protagonist Therapeutics' Other Liab and Common Stock is 0.08. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Common Stock in the same time period over historical financial statements of Protagonist Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagonist Therapeutics' Other Liab and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Protagonist Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Other Liab i.e., Protagonist Therapeutics' Other Liab and Common Stock go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Other Liab

Common Stock

Most indicators from Protagonist Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagonist Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Enterprise Value is likely to rise to about 1.2 B in 2024, whereas Selling General Administrative is likely to drop slightly above 18 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	443K	4.1M	12.9M	13.6M
Net Interest Income	443K	4.1M	12.9M	13.6M

Interest Income Net Interest Income

Protagonist Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Common Stock
Total Assets		0.81	0.83	-0.25	-0.04	0.99	0.72	-0.87	-0.85	0.39	0.87	0.52	0.25	1.0	0.62	0.94	0.96	0.23	-0.03	0.46	0.42	0.3	-0.8	0.87	1.0	0.1
Other Current Liab	0.81		0.61	-0.36	-0.49	0.87	0.45	-0.75	-0.69	0.29	0.73	0.32	-0.19	0.82	0.26	0.78	0.78	0.33	0.08	0.25	0.22	0.37	-0.57	0.69	0.82	0.09
Total Current Liabilities	0.83	0.61		-0.45	0.2	0.83	0.77	-0.69	-0.62	0.55	0.71	0.71	0.54	0.82	0.51	0.73	0.79	0.21	0.11	0.18	0.11	0.29	-0.69	0.72	0.82	0.21
Total Stockholder Equity	-0.25	-0.36	-0.45		-0.16	-0.35	-0.52	-0.09	0.0	-0.57	0.09	-0.58	-0.26	-0.24	0.43	-0.24	-0.32	-0.56	-0.67	0.69	0.71	-0.59	0.22	-0.39	-0.24	-0.01
Other Liab	-0.04	-0.49	0.2	-0.16		-0.12	0.49	0.28	0.05	0.19	-0.22	0.24	0.81	-0.07	0.21	-0.01	0.05	-0.05	0.31	-0.12	-0.15	-0.03	-0.24	0.22	-0.05	0.08
Net Tangible Assets	0.99	0.87	0.83	-0.35	-0.12		0.7	-0.84	-0.81	0.44	0.83	0.56	0.2	0.99	0.52	0.91	0.96	0.28	0.02	0.36	0.32	0.34	-0.77	0.84	0.98	0.03
Property Plant And Equipment Net	0.72	0.45	0.77	-0.52	0.49	0.7		-0.41	-0.59	0.41	0.46	0.54	0.55	0.7	0.39	0.68	0.83	0.26	0.44	0.08	0.04	0.32	-0.75	0.86	0.71	0.19
Net Debt	-0.87	-0.75	-0.69	-0.09	0.28	-0.84	-0.41		0.91	-0.26	-1.0	-0.3	-0.07	-0.87	-0.72	-0.86	-0.74	-0.23	0.39	-0.73	-0.69	-0.28	0.71	-0.66	-0.87	-0.19
Retained Earnings	-0.85	-0.69	-0.62	0.0	0.05	-0.81	-0.59	0.91		-0.25	-0.92	-0.28	-0.14	-0.86	-0.7	-0.92	-0.8	-0.41	0.24	-0.72	-0.69	-0.45	0.84	-0.85	-0.86	-0.17
Accounts Payable	0.39	0.29	0.55	-0.57	0.19	0.44	0.41	-0.26	-0.25		0.26	0.38	0.64	0.39	0.19	0.4	0.37	0.38	0.35	-0.2	-0.23	0.42	-0.62	0.32	0.39	0.08
Cash	0.87	0.73	0.71	0.09	-0.22	0.83	0.46	-1.0	-0.92	0.26		0.31	0.12	0.87	0.76	0.86	0.76	0.22	-0.37	0.74	0.7	0.27	-0.74	0.69	0.87	0.2
Non Current Assets Total	0.52	0.32	0.71	-0.58	0.24	0.56	0.54	-0.3	-0.28	0.38	0.31		0.36	0.51	0.09	0.39	0.5	0.37	-0.06	-0.14	-0.16	0.42	-0.25	0.44	0.49	-0.36
Other Assets	0.25	-0.19	0.54	-0.26	0.81	0.2	0.55	-0.07	-0.14	0.64	0.12	0.36		0.23	0.45	0.25	0.27	-0.02	0.28	-0.04	-0.09	0.03	-0.54	0.31	0.24	0.17
Cash And Short Term Investments	1.0	0.82	0.82	-0.24	-0.07	0.99	0.7	-0.87	-0.86	0.39	0.87	0.51	0.23		0.61	0.94	0.96	0.24	-0.04	0.46	0.42	0.3	-0.79	0.86	1.0	0.1
Net Receivables	0.62	0.26	0.51	0.43	0.21	0.52	0.39	-0.72	-0.7	0.19	0.76	0.09	0.45	0.61		0.59	0.56	-0.24	-0.38	0.84	0.8	-0.2	-0.7	0.47	0.62	0.09
Common Stock Shares Outstanding	0.94	0.78	0.73	-0.24	-0.01	0.91	0.68	-0.86	-0.92	0.4	0.86	0.39	0.25	0.94	0.59		0.88	0.43	-0.02	0.5	0.45	0.48	-0.86	0.92	0.95	0.24
Short Term Investments	0.96	0.78	0.79	-0.32	0.05	0.96	0.83	-0.74	-0.8	0.37	0.76	0.5	0.27	0.96	0.56	0.88		0.18	0.14	0.37	0.33	0.24	-0.8	0.9	0.96	0.05
Non Current Liabilities Total	0.23	0.33	0.21	-0.56	-0.05	0.28	0.26	-0.23	-0.41	0.38	0.22	0.37	-0.02	0.24	-0.24	0.43	0.18		0.07	-0.13	-0.12	1.0	-0.32	0.45	0.22	0.08
Inventory	-0.03	0.08	0.11	-0.67	0.31	0.02	0.44	0.39	0.24	0.35	-0.37	-0.06	0.28	-0.04	-0.38	-0.02	0.14	0.07		-0.66	-0.69	0.08	-0.16	0.21	-0.03	0.33
Other Current Assets	0.46	0.25	0.18	0.69	-0.12	0.36	0.08	-0.73	-0.72	-0.2	0.74	-0.14	-0.04	0.46	0.84	0.5	0.37	-0.13	-0.66		0.99	-0.12	-0.45	0.34	0.47	0.08
Other Stockholder Equity	0.42	0.22	0.11	0.71	-0.15	0.32	0.04	-0.69	-0.69	-0.23	0.7	-0.16	-0.09	0.42	0.8	0.45	0.33	-0.12	-0.69	0.99		-0.12	-0.41	0.29	0.43	-0.01
Total Liab	0.3	0.37	0.29	-0.59	-0.03	0.34	0.32	-0.28	-0.45	0.42	0.27	0.42	0.03	0.3	-0.2	0.48	0.24	1.0	0.08	-0.12	-0.12		-0.37	0.5	0.29	0.09
Long Term Investments	-0.8	-0.57	-0.69	0.22	-0.24	-0.77	-0.75	0.71	0.84	-0.62	-0.74	-0.25	-0.54	-0.79	-0.7	-0.86	-0.8	-0.32	-0.16	-0.45	-0.41	-0.37		-0.83	-0.8	-0.24
Property Plant And Equipment Gross	0.87	0.69	0.72	-0.39	0.22	0.84	0.86	-0.66	-0.85	0.32	0.69	0.44	0.31	0.86	0.47	0.92	0.9	0.45	0.21	0.34	0.29	0.5	-0.83		0.87	0.21
Total Current Assets	1.0	0.82	0.82	-0.24	-0.05	0.98	0.71	-0.87	-0.86	0.39	0.87	0.49	0.24	1.0	0.62	0.95	0.96	0.22	-0.03	0.47	0.43	0.29	-0.8	0.87		0.12
Common Stock	0.1	0.09	0.21	-0.01	0.08	0.03	0.19	-0.19	-0.17	0.08	0.2	-0.36	0.17	0.1	0.09	0.24	0.05	0.08	0.33	0.08	-0.01	0.09	-0.24	0.21	0.12

Click cells to compare fundamentals

Protagonist Therapeutics Account Relationship Matchups

Protagonist Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	154.9M	324.5M	347.7M	247.9M	358.0M	204.1M
Other Current Liab	(10.2M)	21.2M	38.6M	25.0M	19.4M	13.5M
Total Current Liabilities	35.4M	40.2M	44.0M	31.2M	21.3M	27.7M
Total Stockholder Equity	(217.7M)	(283.8M)	(409.4M)	(536.8M)	336.7M	353.5M
Net Tangible Assets	80.0M	279.6M	300.0M	215.6M	247.9M	141.3M
Property Plant And Equipment Net	7.7M	6.4M	6.7M	4.6M	2.1M	3.4M
Net Debt	(16.0M)	(111.4M)	(117.8M)	(122.1M)	(185.6M)	(176.3M)
Retained Earnings	(217.7M)	(283.8M)	(409.4M)	(536.8M)	(615.7M)	(584.9M)
Accounts Payable	2.8M	3.1M	1.6M	3.6M	772K	733.4K
Cash	33.0M	117.4M	123.7M	125.7M	186.7M	196.1M
Non Current Assets Total	9.6M	8.9M	7.0M	10.6M	2.4M	2.3M
Other Assets	450K	1.1M	1.9M	225K	258.8K	245.8K
Cash And Short Term Investments	133.0M	307.8M	326.9M	237.4M	341.6M	191.4M
Net Receivables	6.8M	3.5M	4.4M	52K	10.3M	10.8M
Common Stock Shares Outstanding	25.9M	34.4M	46.3M	49.0M	56.8M	29.8M
Short Term Investments	100.0M	188.5M	203.2M	111.6M	154.9M	99.8M
Liabilities And Stockholders Equity	(142.7M)	(238.9M)	(361.7M)	247.9M	358.0M	375.8M
Non Current Liabilities Total	39.5M	4.6M	3.7M	784.7M	221K	210.0K
Inventory	4.8M	4.0M	8.5M	(94K)	(10.3M)	(9.8M)
Other Current Assets	744K	311K	975K	42K	14.0M	14.7M
Other Stockholder Equity	221K	(28K)	299K	359K	952.5M	1.0B
Total Liab	75.0M	44.9M	47.7M	784.7M	21.3M	20.2M
Property Plant And Equipment Gross	7.7M	6.4M	11.0M	9.9M	8.4M	5.1M
Total Current Assets	145.3M	315.6M	340.7M	237.4M	355.6M	196.9M
Accumulated Other Comprehensive Income	(221K)	28K	(299K)	(359K)	(105K)	(110.3K)
Property Plant Equipment	7.7M	1.5M	6.7M	1.6M	1.8M	2.5M
Capital Surpluse	297.8M	563.4M	709.7M	752.7M	865.6M	908.9M
Retained Earnings Total Equity	(217.7M)	(283.8M)	(409.4M)	(536.8M)	(483.1M)	(458.9M)
Current Deferred Revenue	41.5M	14.5M	1.6M	69K	3K	2.9K
Net Invested Capital	89.8M	279.6M	300.0M	215.6M	336.7M	228.6M
Net Working Capital	109.9M	275.4M	296.7M	211.9M	334.3M	227.5M
Short Term Debt	1.3M	1.5M	2.2M	2.5M	1.1M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protagonist Other Liab vs Common Stock Analysis

Other Liab vs Common Stock

Other Liab vs Common Stock Correlation Analysis

Correlation Coefficient

Other Liab

Common Stock

Protagonist Therapeutics fundamental ratios Correlations

Protagonist Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protagonist Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Protagonist Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Net Tangible Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Net Tangible Assets

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Cash	- 0.92	Retained Earnings
Total Current Assets	- 0.87	Net Debt
Cash And Short Term Investments	- 0.87	Net Debt
Net Debt	- 0.87	Total Assets